Paq Therapeutics, Inc.
Clinical trials sponsored by Paq Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug PT0253 targets Hard-to-Treat KRAS G12D cancers Results expected Dec 2026 (estimated)
-
New drug PT0253 targets Hard-to-Treat KRAS G12D cancers
Disease control Recruiting nowThis early-phase study tests a new drug called PT0253 in about 115 adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have …
Phase 1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug PT0511 targets Hard-to-Treat KRAS cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…
Phase 1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC